Tonix Pharmaceuticals Announces Acceptance of Two Fibromyalgia-Related Abstracts for Presentation at EULAR

Tonix Pharmaceuticals Announces Acceptance of Two Fibromyalgia-Related Abstracts for Presentation at EULAR
Tonix Pharmaceuticals Holding Corp, a clinical-stage firm currently advancing next-generation medicines to address the unmet needs related to post-traumatic stress disorder, fibromyalgia, and episodic tension-type headache, recently announced that two of the company's abstracts were accepted and will be presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, Italy. The studies that will be presented will cover the efficacy of TNX-102 SL to treat patients with fibromyalgia. Fibromyalgia symptoms include chronic musculoskeletal pain, incapacitating fatigue, stiffness and numbness in certain parts of the body, painful response to pressure, headaches, unrefreshing sleep (poor sleep quality), anxiety or depression and mood alterations. The disease can compromise the ability to perform simple daily tasks and estimates say that 5 to 15 million Americans are affected by this disorder, especially women. The two accepted abstracts are "TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement" to be presented by R. Michael Gendreau, M.D., Ph.D., Principal, Gendreau Consulting on June 11 between 12:00 p.m. and 1:45 p.m; and “TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization” that will be presented by Seth Lederman, M.D., CEO, Tonix Pharmaceuticals on June 11 between 12:00 p.m. and 1:45 p.m. More details about these presentations can be found at
Subscribe or to access all post and page content.